There are currently 425 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and Alliance for Childhood Diseases/Cure 4 the Kids Foundation. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Recruiting
This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
02/27/2025
Locations: Cancer and Blood Specialists-Shadow, Las Vegas, Nevada +9 locations
Conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Ergonomic Protocol for Competitive E-Sport Athletes
NCT06781580
Recruiting
The goal of this clinical trial is to learn if this ergonomic protocol can improve performance and reduce ergonomic risk in esports athletes. It will also learn about the insight of esports athletes and their experience in implementing this new protocol. The main questions it aims to answer are: Does this ergonomic protocol improve performance? Does this ergonomic protocol reduce ergonomic risk? Researchers will assign the protocol to esports athletes who meet inclusion criteria and express in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: University of Nevada, Las Vegas, Las Vegas, Nevada
Conditions: No Disease or Condition is Being Studied
Register for Updates
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
NCT06153420
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Las Vegas Medical Research, Las Vegas, Nevada +1 locations
Conditions: Irritable Bowel Syndrome With Diarrhea
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688
Recruiting
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: OptumCare Cancer Care at Charleston, Las Vegas, Nevada +1 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: OptumCare Cancer Care at Charleston, Las Vegas, Nevada +1 locations
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
NCT06830629
Recruiting
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: AB Clinical Trials, Las Vegas, Nevada
Conditions: Proteinuric Kidney Disease
Register for Updates
Freedom-1 Study for Chronic Knee Pain
NCT03877653
Recruiting
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Desert Orthopaedic Center, Las Vegas, Nevada
Conditions: Osteoarthritic Knee Pain
Register for Updates
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
NCT05193929
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Viable Research Management, Las Vegas, Nevada
Conditions: Diabetic Foot Ulcer
Register for Updates
Problem Behavior Assessment and Intervention in IDEA Part C Services
NCT06771284
Recruiting
The purpose of this study is to evaluate the effect of function-based assessment and intervention to reduce problem behavior in children with developmental disability or delay in the context of IDEA Part C services. The investigators will conduct a single-case study to evaluate the efficacy of the intervention.
Gender:
ALL
Ages:
Between 0 months and 5 years
Trial Updated:
02/03/2025
Locations: University of Nevada Las Vegas, Las Vegas, Nevada
Conditions: Problem Behavior, Developmental Delay, Developmental Disability
Register for Updates
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass
NCT06566716
Recruiting
Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the cu... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Ovarian Neoplasms
Register for Updates
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06810050
Recruiting
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 w... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/30/2025
Locations: JDR Dermatology Research, Las Vegas, Nevada
Conditions: Atopic Dermatitis (AD)
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Valley Hospital and Medical Center, Las Vegas, Nevada
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates